Abstract
Worldwide, there are more than 8 million new cases of Mycobacterium tuberculosis (TB) and 3 million deaths each year. In the United States, approx 15 million people are infected with TB. In 1965, shortly after isoniazid was found to be effective for the treatment of TB, the first recommendation for treating latent M. tuberculosis infection (LTBI) in the general population was given. The American Thoracic Society recommended that all persons with evidence of previously untreated TB, with recent tuberculin test conversions, and all children younger than 3 yr of age with a positive tuberculin skin test (TST) should be treated with isoniazid. Despite broadened recommendations in 1967 and a more widespread number of people being treated with an inexpensive drug that was thought to have few side effects, the morbidity from TB never dramatically fell as had been projected. When the hepatotoxicity of isoniazid began to be recognized in the early 1970s a controversy erupted over what would be the appropriate age cutoff in low-risk people that would ensure the benefits of therapy for LTBI and outweigh the risks of treatment. Rifampin (RIF) was introduced for the treatment of LTBI in the early 1980s because the real and perceived problems with isoniazid’s hepatotoxicity and the long period of treatment required with isoniazid had impaired isoniazid’s widespread usefulness.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Sources
Diagnostic Standards and Classification of Tuberculosis in Adults and Children (2000) Am J Respir Crit Care Med 161:1376–1395.
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. Joint Statement of the American Thoracic Society and the Centers for Disease Control and Prevention (2000) Am J Respir Crit Care Med 161:S221–S247.
MMWR Aug. 31, 2001;50:733.
Guidelines for Using the QuantiFERON®-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United States. MM WR December 16, 2005;54:49.
MMWR 200; 50:733.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Fenstemacher, P. (2007). Tuberculosis Testing and Treatment of Latent Infection. In: Skolnik, N.S., Schneider, D., Neill, R., Kuritzky, L. (eds) Essential Practice Guidelines in Primary Care. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-313-4_16
Download citation
DOI: https://doi.org/10.1007/978-1-59745-313-4_16
Publisher Name: Humana Press
Print ISBN: 978-1-58829-508-8
Online ISBN: 978-1-59745-313-4
eBook Packages: MedicineMedicine (R0)